Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Regeneron

U.S. FDA Accepts Regeneron's Diabetic Retinopathy Candidate Submission For Review

The U.S. Food and Drug Administration (FDA) has accepted Regeneron Pharmaceuticals’ (NASDAQ: REGN) supplemental Biologics License Application (sBLA) of EYLEA (aflibercept) Injection for review in patients with diabetic retinopathy (DR).

Benzinga

U.S. FDA Approves Regeneron And Sanofi's Lead Drug For Skin Inflammation In Children

The U.S.

Benzinga

Stock Market Near Session Lows; These Health Care Leaders Tumble

The stock market gave back most of its early gains and traded near session lows in afternoon trading. Amazon.com rose in the first day of its stock split.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Regeneron Pharmaceuticals Dives On $1.1 Billion Deal To Rival Merck In Cancer

Regeneron stock tumbled Thursday after the company announced a deal to acquire the international rights to Sanofi-partnered cancer drug Libtayo.

Investors Business Daily

Oil Stocks Lead Charge Of Breakouts And Buy Zones In New Uptrend

With a new uptrend underway, oil stocks like TotalEnergies and tech stocks like Synopsys set the stage for new breakouts.

Investors Business Daily

FDA Accepts Regeneron, Sanofi's Filing For Review In Skin Disease

The U.S.

Benzinga

FDA Approves Regeneron and Sanofi's Dupixent (dupilumab) For Eosinophilic Esophagitis (EoE) Ahead of Schedule

The U.S. Food and Drug Administration (FDA) has approved Regeneron Pharmaceuticals, Inc.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Why Tech Leader Regeneron Shouldn't Sweat Its AbbVie Rival — For Now

AbbVie could soon pressure Regeneron in eczema treatment, an analyst said Friday as Regeneron stock hit a ceiling at its 200-day line.

Investors Business Daily

Regeneron Posts Drop In Q1 Profit As COVID Antibody Sales Hit, Shares Fall

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) earned $11.49 per share for Q1 FY22, up 16% Y/Y, beating the $10.04 estimate. Sales increased 17% to $2.96 billion, surpassing the analysts' consensus of $2.73 billion, fueled by sales of COVID-19 treatment, REGEN-COV. The company reported a net income of $974 million, down 13%, as its COVID-19…

Benzinga

Why The First Quarter Could Be A 'High-Water Mark' For Regeneron

The first quarter could represent a "high-water mark" for Regeneron Pharmaceuticals, an analyst said Wednesday.

Investors Business Daily

Here's Why This Analyst Cut Price Target On Regeneron

RBC Capital Markets has lowered Regeneron Pharmaceuticals Inc's price target (NASDAQ:REGN) from $679 to $647 and maintained a Sector Perform rating. Checks suggest that Dupixent (dupilumab) growth/durability should remain strong in new and existing indications, maintaining positive sentiment. The analysts also believe that the concerns about near-term Eylea competition may be overblown. However, high-dose…

Benzinga

The Daily Biotech Pulse: Regeneron Acquires Checkmate Pharma, Moderna's Bivalent Booster COVID-19 Vaccine Update, Priority Review For AstraZeneca's Enhertu

Here's a roundup of top developments in the biotech space over the last 24 hours.

Benzinga

Checkmate Pharma Shares Skyrocket Over 300% On Regeneron $250M Acquisition Deal

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) will acquire Checkmate Pharmaceuticals Inc (NASDAQ:CMPI) for $10.50 per share, equivalent to a total equity value of approximately $250 million. Checkmate is a clinical-stage biopharmaceutical company focused on proprietary technology to harness the immune system's power to combat cancer. The offer price represents a whopping premium of over 300% on…

Benzinga

Why Checkmate Pharmaceuticals Shares Are Skyrocketing

Checkmate Pharmaceuticals Inc (NASDAQ: CMPI) shares are trading higher by 328.40% to $10.41 during Tuesday's pre-market session after Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced a deal to acquire the comp

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Booster Data In Kids, Regeneron's COVID-19 Therapy Decision Pushed, Protagonist's Rusfertide Breakthrough Tag Update And More

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

FDA Extends Review Period For Regeneron's COVID-19 Antibody Therapy

The FDA has extended its review of Regeneron Pharmaceuticals Inc's (NASDAQ:REGN) marketing application of REGEN-COV (casirivimab and imdevimab) for non-hospitalized COVID-19 patients and as prophylaxis in certain individuals. The extension is due to ongoing discussions with the FDA on pre-exposure prophylactic use. Regeneron has submitted additional data from its completed prophylaxis trial that the…

Investors Business Daily

IBD 50 Stocks To Watch: Biotech Regeneron Remains In Buy Zone As Market Waffles

This maker of drugs to treat eye and inflammatory diseases as well as cancer remains in a buy zone even as the stock market rally struggles.

Benzinga

Regeneron Builds On Retinal Disease Expertise Via Gene Therapy Pact With ViGeneron

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) beefed up its gene therapy capabilities after signing a new deal with the German biotech ViGeneron. The companies did not specify their target but noted it would be some inherited retinal disease. It's an area where Regeneron has much expertise. One of its best-selling products, Eylea, is approved to treat…

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Dow Jones Falls; Tesla Rises Despite 'Exceptionally Difficult Quarter'; Twitter Soars On Musk Stake

The Dow Jones Industrial Average fell Monday, as Tesla climbed after the company reported record vehicle deliveries.

Benzinga

Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates

Biopharma stocks are sensitive to a key binary event called the PDUFA date, the date by which the Food and Drug Administration is required to give its verdict on a regulatory application filed with it.

Investors Business Daily

Dow Jones Rallies After March Jobs Report Miss; Treasury Yields Surge

The Dow Jones Industrial Average rallied Friday after the March jobs report miss. The 10-year Treasury yield surged.

Investors Business Daily

Dow Jones Falls; Oil Prices Dive As U.S. Eyes Reserve Release

The Dow Jones Industrial Average fell Thursday. Oil prices dived on news that the Biden administration is planning to tap U.S. oil reserves.

Investors Business Daily

Dow Jones Futures Rise, Oil Prices Tumble; Tesla Jumps On Stock Split Plan

The market rally has been strong despite surging bond yields, but for now. Tesla popped on plans for a stock split.

Investors Business Daily

Dow Jones Futures: Market Rally Near Lows Amid Ukraine Invasion, Looming Fed Rate Hike, Covid's Return

Russia's Ukraine invasion, a looming Fed rate hike and the return of Covid are big headwinds as the major indexes near their Feb. 24 lows.

Investors Business Daily

Dow Jones Futures: Market Rally Nears Lows Amid Ukraine Invasion, Looming Fed Rate Hike; What To Do Now

Russia's Ukraine invasion and a looming Fed rate hike are big headwinds as the major indexes nearing their Feb. 24 lows.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.